Updates
** Shares of Intra-Cellular Therapies ITCI.O rise as much as 35% to a record high of $128, after Johnson & Johnson JNJ.N agrees to buy the drugmaker for about $14.6 bln
** JNJ said it will buy all of ITCI's shares for $132 each, representing a 39% premium to its Friday closing price
** Deal gives J&J access to ITCI's oral drug Caplyta, approved for schizophrenia and bipolar disorder-related depression
** Caplyta is also under review as an add-on therapy for major depressive disorder
** At least three analysts said the deal was a good fit for J&J's existing portfolio of brain disease treatments, which includes schizophrenia drug paliperidone sold under multiple brand names
** Needham analysts said in a note that investors could focus on J&J's late-stage depression drug aticaprant and its overlap with Caplyta
** "However, it may not be a direct competitor to Caplyta as it has a different mechanism," said Needham analysts, adding that the drug also targets a subset of patients with depression
** Companies expect to close the deal later this year
** J&J shares up marginally at $142.61; stock fell ~8% in 2024
** ITCI rose 16.6% in 2024
(Reporting by Puyaan Singh and Bhanvi Satija)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.